MX2023004633A - Moduladores del atenuador de linfocitos b y t (btla) y metodo de uso de los mismos. - Google Patents

Moduladores del atenuador de linfocitos b y t (btla) y metodo de uso de los mismos.

Info

Publication number
MX2023004633A
MX2023004633A MX2023004633A MX2023004633A MX2023004633A MX 2023004633 A MX2023004633 A MX 2023004633A MX 2023004633 A MX2023004633 A MX 2023004633A MX 2023004633 A MX2023004633 A MX 2023004633A MX 2023004633 A MX2023004633 A MX 2023004633A
Authority
MX
Mexico
Prior art keywords
btla
modulators
same
lymphocyte attenuator
binding agent
Prior art date
Application number
MX2023004633A
Other languages
English (en)
Inventor
Marilyn Kehry
Stephen Parmley
Martin Edward Dahl
Jean Da Silva Correia
Morena Shaw
Original Assignee
Anaptysbio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anaptysbio Inc filed Critical Anaptysbio Inc
Publication of MX2023004633A publication Critical patent/MX2023004633A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Un agente de unión a BTLA y polipéptidos de cadena pesada y de cadena ligera de inmunoglobulina del agente de unión, así como métodos de uso del agente de unión a BTLA para tratar un trastorno o enfermedad que responde al agonismo de BTLA, tal como una enfermedad autoinmune o inflamatoria.
MX2023004633A 2020-10-23 2021-10-22 Moduladores del atenuador de linfocitos b y t (btla) y metodo de uso de los mismos. MX2023004633A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063105067P 2020-10-23 2020-10-23
US202163192984P 2021-05-25 2021-05-25
PCT/US2021/056289 WO2022087441A2 (en) 2020-10-23 2021-10-22 B and t lymphocyte attenuator (btla) modulators and method of using same

Publications (1)

Publication Number Publication Date
MX2023004633A true MX2023004633A (es) 2023-05-12

Family

ID=78695822

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023004633A MX2023004633A (es) 2020-10-23 2021-10-22 Moduladores del atenuador de linfocitos b y t (btla) y metodo de uso de los mismos.

Country Status (9)

Country Link
US (1) US20230391872A1 (es)
EP (1) EP4232480A2 (es)
JP (1) JP2023546713A (es)
KR (1) KR20230096024A (es)
AU (1) AU2021365611A1 (es)
CA (1) CA3196493A1 (es)
IL (1) IL302135A (es)
MX (1) MX2023004633A (es)
WO (1) WO2022087441A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023212611A1 (en) * 2022-04-27 2023-11-02 Anaptysbio, Inc. B and t lymphocyte attenuator (btla) modulators and method of using same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4828981A (en) 1983-08-24 1989-05-09 Synbiotics Corporation Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
EP0557459B1 (en) 1990-11-13 1997-10-22 Immunex Corporation Bifunctional selectable fusion genes
EP0804590A1 (en) 1993-05-21 1997-11-05 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
FR2814642B1 (fr) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
EP2126105A4 (en) 2007-02-20 2010-11-03 Anaptysbio Inc SOMATIC HYPERPERMUTATION SYSTEMS
KR20120090037A (ko) * 2009-07-31 2012-08-16 메다렉스, 인코포레이티드 Ｂｔｌａ에 대한 완전 인간 항체
JOP20190261A1 (ar) * 2017-05-19 2019-11-05 Lilly Co Eli أجسام مضادة لعامل مساعد لـ btla واستخداماتها
GB201820554D0 (en) * 2018-12-17 2019-01-30 Univ Oxford Innovation Ltd BTLA antibodies
US11384146B2 (en) * 2019-04-01 2022-07-12 Curia Ip Holdings, Llc BTLA-binding antibodies for modulating immune response and treating disease

Also Published As

Publication number Publication date
CA3196493A1 (en) 2022-04-28
US20230391872A1 (en) 2023-12-07
WO2022087441A2 (en) 2022-04-28
KR20230096024A (ko) 2023-06-29
AU2021365611A1 (en) 2023-06-08
WO2022087441A3 (en) 2022-08-25
JP2023546713A (ja) 2023-11-07
IL302135A (en) 2023-06-01
EP4232480A2 (en) 2023-08-30

Similar Documents

Publication Publication Date Title
PH12021551171A1 (en) Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof
MX2019012793A (es) Agentes anticuerpos dirigidos contra el gen de activación de linfocitos-3 (lag-3) y usos de los mismos.
MX2023004633A (es) Moduladores del atenuador de linfocitos b y t (btla) y metodo de uso de los mismos.
MX2018013242A (es) Metodo, aparato y programa de computadora para generar sistemas de aprendizaje automatizados, robustos y sistemas de aprendizaje automatizados formados de prueba.
EA201990285A1 (ru) Гетеродимерные иммуноглобулиновые конструкции и способы их получения
CO2020010345A2 (es) Dominios variables de anticuerpos que se dirigen al receptor nkg2d
MX2021005155A (es) Anticuerpo biespecífico y uso del mismo.
AU2020329881A8 (en) Cell-surface receptors responsive to loss of heterozygosity
AR111752A1 (es) Anticuerpos agonistas contra el atenuador de linfocitos b y t (btla) y sus usos
MX2021010510A (es) Mezclado controlado de fracciones de transmezcla en corrientes de hidrocarburo definidas.
DE60334442D1 (de) Verfahren und system zum identifizieren und überwachen von verstärker verkehr in einem cdma system
RS53578B1 (en) CXCR4 ANTIBODIES AND THEIR USE FOR CANCER TREATMENT
PE20190212A1 (es) Anticuerpos anti_ige
BR112016003369A2 (pt) diacorpos monovalentes biespecíficos, diacorpos fc monovalentes biespecíficos, composição farmacêutica, uso da composição farmacêutica, célula que expressa uma cadeia de polipeptídeo de quaisquer dos diacorpos monovalentes biespecíficos, polinucleotídeo que codifica o polipeptídeo, e célula que expressa um anticorpo ou uma porção de polipeptídeo ou fragmento da mesma
BR112022000953A2 (pt) Filtro de loop adaptável de componente cruzado para croma
MX2020000055A (es) Anticuerpos biespecificos antiproteina 1 de muerte celular programada (pd-1) -anti inmunoglobulina de celulas t y dominio de mucina que contiene -3 (tim-3).
BR112021026890A2 (pt) Composições de anticorpo para interromper biofilmes
NO20076568L (no) Anti-IL2 antistoffer
EP4273892A3 (en) Systems, methods and tools for the interrogation of composite strength members
AR117565A1 (es) Agentes de unión a c3 y método de uso de los mismos
MX2020011588A (es) Anticuerpos de alta afinidad a pd-1 y lag-3 y proteinas de union bispecificas preparadas a partir de las mismas.
MX2021015054A (es) Agonista de pd-1 y metodo para usar el mismo.
MX2021005323A (es) Metodos de tratar la oftalmopatía de graves mediante el uso de anticuerpos anti-fcrn.
CO2021006953A2 (es) Anticuerpos anti-claudina 18.2 y anti-4-1bb bispecificos y su uso
EP4268848A3 (en) Monospecific and bispecific proteins with immune checkpoint regulation for cancer therapy